ARGX — Recent News Coverage

ARGX announced a material acquisition of Forte Biosciences, signaling aggressive portfolio expansion in the immunology and dermatology space. This M&A event represents a strategic capital deployment decision by the Belg…

argenx announced a $2.2 billion acquisition of Forte Biosciences, signaling aggressive M&A momentum in the biopharma sector. This deal represents a substantial capital deployment and signals management confidence in vit…

argenx SE (ARGX) held an M&A call on July 27, 2026, signaling material corporate activity within the immunology and rare disease space. M&A announcements in biopharmaceuticals typically carry high market relevance, as t…

FBRX surged 39.2% on announcement of a $2.2 billion all-cash acquisition by ARGX, representing a significant M&A event in the clinical-stage biotech space. The transaction premium reflects argenx's strategic interest in…

argenx announced a $2.2 billion acquisition of Forte Biosciences, representing a significant consolidation in the specialty immunology and dermatology space. This deal signals continued M&A momentum in the biotech secto…

Argenx has announced a $2.2 billion cash acquisition of Forte Biosciences at $77 per share, representing a significant consolidation move in the immunology and dermatology therapeutic space. This deal signals accelerate…

argenx announced a $2.2 billion cash acquisition of Forte Biosciences at $77 per share, a significant M&A event in the immunology space. The deal adds FB102, a first-in-class anti-CD122 antibody, to argenx's existing im…

Wall Street absorbed significant headwinds on July 23 as over 150 companies reported second-quarter earnings while the US Trade Representative simultaneously announced tariff increases of 10% to 12.5% on targeted sector…